ArticleThe Journal of clinical investigation2013
BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.
Article in The Journal of clinical investigation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 480 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
480 citing papers in PubMed, 1 synthesis or guideline pooled it, 779 citations in OpenAlex.
- Mesenchymal Stromal Cell-derived Extracellular Vesicles in Preclinical Animal Models of Tumor Growth: Systematic Review and Meta-analysis.Stem cell reviews and reports · 2022Pooled it
- Article
- Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies.European journal of haematology · 2026Review
- Review
- Breaking the Balance: Baseline Oxidative Stress and DNA Repair Capacity in Multiple Myeloma Therapy.Cancers · 2026Article
- Extracellular vesicle cargo dynamics in the bone marrow microenvironment: from hematopoietic homeostasis to malignant transformation.Extracellular vesicle · 2026Article
- Extracellular Enolase-1 Promotes CAF-Associated Stromal Reprogramming via the Plasmin/TGF-β Axis in Multiple Myeloma.Cancers · 2026Article
- Deciphering epigenetic crosstalk in multiple myeloma pathogenesis and treatment.Clinical epigenetics · 2026Review
- The Status of Extracellular Vesicles as Drug Carriers and Therapeutics.Nature reviews bioengineering · 2026Article
- Rearming mesenchymal stem cells with engineering strategies to combat cancer.Frontiers in immunology · 2026Review
- Targeting Strategies of Stem Cell-Derived Extracellular Vesicles in the Treatment of Cardiovascular Diseases.Stem cell reviews and reports · 2026Review
- AI-derived five-gene signature predicts risk in multiple myeloma under bortezomib-based therapy.Scientific reports · 2025Article
- Engineered mesenchymal stem cell-derived exosomes: A revolutionary approach to unlocking liver disease treatment.Biochemistry and biophysics reports · 2025Review
- Extracellular vesicles in multiple myeloma-bone marrow niche crosstalk: from cellular dialogue to clinical perspectives.Journal of translational medicine · 2025Review
- Article
- Proinflammatory bone marrow niches and neutrophil activation are associated with TIGIT expression in multiple myeloma.Annals of hematology · 2025Article
- Sex-specific dysregulation of exosomal non-coding RNAs drives multiple myeloma progression.Blood cancer journal · 2025Article
- Mesenchymal stem cells and cancer stem cells promote colorectal cancer cell growth and biological functions via cell-cell indirect contact.Cancer cell international · 2025Article
- Umbilical cord blood-derived exosomes deliver miR-182-5p to Therapeutically target the MYD88/NF-κB signaling pathway in rat peri-implantitis.Materials today. Bio · 2025Article
- Extracellular vesicles in multiple myeloma: pathogenesis and therapeutic application.The FEBS journal · 2025Review
420 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
BM mesenchymal stromal cells (BM-MSCs) support multiple myeloma (MM) cell growth, but little is known about the putative mechanisms by which the BM microenvironment plays an oncogenic role in this disease. Cell-cell communication is mediated by exosomes. In this study, we showed that MM BM-MSCs release exosomes that are transferred to MM cells, thereby resulting in modulation of tumor growth in vivo. Exosomal microRNA (miR) content differed between MM and normal BM-MSCs, with a lower content of the tumor suppressor miR-15a. In addition, MM BM-MSC-derived exosomes had higher levels of oncogenic proteins, cytokines, and adhesion molecules compared with exosomes from the cells of origin. Importantly, whereas MM BM-MSC-derived exosomes promoted MM tumor growth, normal BM-MSC exosomes inhibited the growth of MM cells. In summary, these in vitro and in vivo studies demonstrated that exosome transfer from BM-MSCs to clonal plasma cells represents a previously undescribed and unique mechanism that highlights the contribution of BM-MSCs to MM disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.